drugset / Trial / NCT04205630
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Timeline
- Start
- 2020-05-28
- Primary completion
- 2023-01-26
- Completion
- 2023-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab duocarmazine | Other / unclassified | — | Intravenous |